article thumbnail

A perfect storm for biotech stocks

World of DTC Marketing

It dropped more than 15% in 2016 and followed that up with a 44% rise in 2017. Meanwhile, the Food and Drug Administration has delayed several drug approvals, and Sen. introduced sweeping drug-pricing legislation. 1ne: More scrutinization by the FDA on new drug applications. Bernie Sanders, I-Vt.,

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma 210
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moderna files lawsuits against Pfizer and BioNTech over mRNA technology

Pharmaceutical Technology

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, is said to have infringed patents filed by Moderna between 2010 and 2016 for its mRNA technology. The latest development comes after Moderna sought emergency use authorization from the US Food and Drug Administration for its BA.4/BA.5

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

article thumbnail

Transforming pharmaceutical manufacturing: The AI revolution

European Pharmaceutical Review

Accelerated drug discovery: Simulations and predictive models powered by AI will speed up the drug development process, effectively slashing time to market for drugs. Internet] US Food and Drug Administration (FDA). 2016; 85(4):2048-2050. 2016; 12(7):878. Tuijin Jishu / Propuls. cited 2023Dec].

article thumbnail

Telix revives Olaratumab development with positive preclinical data

Pharmaceutical Technology

The US Food and Drug Administration (FDA) granted Eli Lilly’s Lartruvo (olaratumab) accelerated approval in 2016 for soft tissue sarcoma (STS). The US Food and Drug Administration (FDA) granted Eli Lilly’s Lartruvo (olaratumab) accelerated approval in 2016 for soft tissue sarcoma (STS).

article thumbnail

First biosimilar to HUMIRA® available in US

European Pharmaceutical Review

Amgen’s AMJEVITA was the first biosimilar to Humira approved by the US Food and Drug Administration (FDA), in 2016. AMJEVITA (adalimumab-atto), a biosimilar to Humira ® (adalimumab), is now available in the US. The active ingredient in the anti-TNF-α monoclonal antibody has the same amino acid sequence as Humira.